leadf
logo-loader
viewVictory Square Technologies Inc

A Covid vaccine is still months away; meet the companies preparing to wage war against the coronavirus

Presenting are five companies at the forefront of developing rapid solutions for testing and real-time track and trace

Victory Square Technologies Inc -
The event is a not-to-be-missed opportunity to find out what’s new in the battle against this pernicious virus

With a coronavirus vaccine still months away, the two-Ts – testing and tracing – remain critically important elements in controlling the outbreak, and by extension minimizing fatalities.

In our latest One2One Virtual Forum we have five companies at the forefront of developing rapid solutions for testing and real-time track and trace that puts privacy at its heart.

This is a not-to-be-missed opportunity to find out what’s new in the battle against this pernicious virus.

Join us at 1pm EST on Tuesday, October 27, from 1pm to hear more.

CLICK HERE TO REGISTER

Victory Square Technologies Inc: A Covid vaccine is still months away; meet a company preparing to wage war against the coronavirus

Victory Square Technologies Inc (CNSX:VEST) has gone from 14 cents to 64 cents in less than two months – and for good reason.

Its portfolio company, Victory Square Health, has come up with a 15-minute COVID-19 test that boasts 96.6% sensitivity.

And, hot off the press, Victory’s Safetest technology has received the official green light for distribution in the 27 countries of the European Union.

Meet Victory Square Technologies’ chief growth officer, Vahid Shababi, at the Proactive Virtual Forum.

CLICK HERE TO REGISTER

Contakt World: Here’s a technology that may prove the difference between success and failure in fighting COVID-19

The difference between success and failure in fighting COVID-19 has been an effective track and trace program.

Contakt World has developed real-time contact tracing for government agencies and business that’s both efficient and accurate.

Crucially, privacy is guaranteed by using blockchain technology to preserve personal information from unauthorized use.

Chief executive Justin Beck will be joining us at the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.

CLICK HERE TO REGISTER

Could LexaGene Holdings Inc’s pathogen detection platform be a difference-maker in the fight against COVID-19?

LexaGene Holdings Inc (CVE:LXG, OTCMKTS:LXXGF) is at the leading edge of med-tech in pioneering the first fully-automated pathogen detection platform for use in diagnostics and sample analysis.

While its MiQLab doesn’t have regulatory sign-off for human clinical diagnostics, LexaGene is pursuing an FDA emergency use authorization for Covid testing, which would open a whole new window of opportunity.

In the meantime, it recently launched an early access program for its MiQLab aimed at the veterinary and open-access markets.

To hear more from CEO and founder Jack Regan, sign up for the Proactive Virtual Forum on Tuesday October 27.

CLICK HERE TO REGISTER

BioPorto Diagnostics A/S is helping develop a ten-minute coronavirus test that could be on the market by the year-end

BioPorto Diagnostics A/S (CPH:BIOPOR) shares have almost doubled in value in little over a month, reflecting the progress it has made with its ten-minute COVID-19 test.

This potentially ground-breaking technology is being developed in harness with the University of Southern Denmark, which brings to the party its antibody expertise.

If successful, the company intends to file for fast-track emergency use in the US along and is pursuing official sign-off for the device in Europe too.

All of this means BioPorto could have its ten-minute test out on the market by the end of the year.

Chief medical officer Christopher Bird will explain all when he presents to the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.

CLICK HERE TO REGISTER

XPhyto Therapeutics Corp could have its rapid disposable coronavirus test on the market early next year

XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF, FRA:4XT) has partnered with a company called 3a-Diagnostics to develop a rapid disposable COVID-19 test.

Work has progressed so rapidly in recent weeks the pair are targeting regulatory approval for the product in the first three months of next year.

Bringing us up to date on progress with areas such as advanced prototype production and usability testing will be CEO Hugh Rogers.

Catch up with Hugh at the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.

CLICK HERE TO REGISTER

About the event:

  • Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
  • We look beyond the numbers and meet the people creating the value for shareholders

The format:

  • Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
  • You can watch the event afterwards on our YouTube channel

CLICK HERE TO REGISTER

Quick facts: Victory Square Technologies Inc

Price: 0.43 CAD

CSE:VST
Market: CSE
Market Cap: $32.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Victory Square Technologies Inc named herein, including the promotion by the Company of Victory Square Technologies Inc in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Itaconix set to 'continue with progress made this year through to next year'

Itaconix PLC's (LON:ITX) John Shaw talks to Proactive London about their first half of the year performance which saw the company’s chemistries used more by major brands in everyday products. He says as revenues increase, they are 'really narrowing losses down' towards goals of reaching break...

3 weeks, 5 days ago